The role of long-acting antibiotics in the clinical practice: a narrative review

Abstract

L ong-acting antibiotics, such as dalbavancin and oritavancin, have emerged as important tools in the fight against bacterial infections. Ini-tially approved for treating acute bacterial skin and skin structure infections (ABSSSI), they have gained attention for potential off-label use due to their extended half-lives, their excellent tissue penetration, which allows prolonged high therapeutic concentrations at the site of infection in many difficult to treat sites as bone, their in vitro demonstrated efficacy against biofilm, their potent activity against a broad spectrum of Gram-positive bacteria, along with a favourable safety pro-

Prescriptive appropriateness of dalbavancin in acute bacterial skin and skin structure infections in adults: an integrated approach between clinical profile, patient- and health system-related factors and focus on environmental impact

“…Long-acting antibiotic strategies offer a promising avenue for reducing antimicrobial resistance (AMR), based on findings that patients receiving extended intravenous antibiotic treatments for more than 14 days face an increased risk of infections (HAIs) (Liu et al, 2023). Transitioning to long-acting antibiotic regimens significantly lowers the chance of encountering care-related infections, thereby reducing the need for further antibiotic interventions and, consequently, the potential for AMR development (Micheli et al, 2023).…”